Oversensing of atrial fibrillatory waves in a subcutaneous implantable cardioverter-defibrillator

Introduction Implantable cardioverter-defibrillators (ICDs) have been shown to improve survival in patients with ischemic or nonischemic cardiomyopathy when used for primary and secondary prevention settings. The limitations of transvenous ICDs include postimplant adverse events, defibrillator lead failure, and inappropriate shocks for atrial tachyarrhythmias due to fast ventricular response rate that are associated with an increase in all-cause mortality. Given these shortcomings, subcutaneous ICDs (S-ICDs) may offer several potential advantages. Prior S-ICD studies have shown a complication rate and shock efficacy comparable to transvenous systems and significantly better supraventricular tachycardia (SVT) discrimination compared to transvenous ICDs. Inappropriate shocks in S-ICDs are almost exclusively due to double counting secondary to Twave oversensing. We report a patient with an S-ICD and hypertrophic cardiomyopathy (HCM) who received an inappropriate shock for atrial fibrillation due to oversensing of atrial fibrillatory waves. This has not been reported previously.

[1]  J. Curtis,et al.  Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation , 2011, Circulation.

[2]  P. Lambiase,et al.  Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. , 2016, Heart rhythm.

[3]  E. Peterson,et al.  Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). , 2014, Journal of the American College of Cardiology.

[4]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[5]  Jeroen J. Bax,et al.  Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator Leads , 2008, Circulation. Arrhythmia and electrophysiology.

[6]  M. Gold,et al.  Head‐To‐Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study , 2012, Journal of cardiovascular electrophysiology.

[7]  J. Barry,et al.  A Case of Inappropriate Therapies for Atrial Flutter From a Subcutaneous ICD , 2014 .

[8]  Wojciech Zareba,et al.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. , 2008, Journal of the American College of Cardiology.

[9]  Jeroen J. Bax,et al.  Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. , 2011, Journal of the American College of Cardiology.

[10]  R. Shephard Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2010 .

[11]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[12]  B. Maron,et al.  Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.

[13]  L. Jordaens,et al.  Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis , 2012, Circulation. Heart failure.

[14]  P. Lambiase,et al.  Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.

[15]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.